Contribute Try STAT+ Today

Amid a growing number of probes into drug makers and patient charities, Pfizer (PFE) has agreed to pay nearly $23.8 million to resolve charges of illegally using a supposedly independent charity to pay kickbacks to Medicare patients as a way to cover their out-of-pocket costs.

Specifically, the Department of Justice alleged that Pfizer used the Patient Access Network Foundation as a conduit to cover co-pay costs for Medicare patients taking three of its drugs, according to the settlement agreement. These drugs were Sutent and Inlyta, which both treat renal cell carcinoma, and Tikosyn, which treats arrhythmia in patients with atrial fibrillation or atrial flutter.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.